{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography&page=11", "query": { "intervention": "Positron emission tomography", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2353, "total_pages": 236, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:07:30.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04532489", "title": "Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Radiotracer", "Hypertension", "Cholesterol" ], "interventions": [ { "name": "FNP-59", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin Viglianti", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-01-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04532489" }, { "nct_id": "NCT01788280", "title": "Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme (GBM)" ], "interventions": [ { "name": "Fluciclitite , PET imaging, and Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-01", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01788280" }, { "nct_id": "NCT00315250", "title": "Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease", "Parkinsonian Syndrome" ], "interventions": [ { "name": "[123I]β-CIT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institute for Neurodegenerative Disorders", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 225, "start_date": "2006-01", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00315250" }, { "nct_id": "NCT07285993", "title": "Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Invasive Lobular Breast Cancer" ], "interventions": [ { "name": "18F-FAPI-74", "type": "DRUG" }, { "name": "18F-FDG", "type": "DRUG" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Randy Yeh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2026-06-01", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285993" }, { "nct_id": "NCT05861050", "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blastoid Variant Mantle Cell Lymphoma", "Mantle Cell Lymphoma", "Pleomorphic Variant Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2023-08-10", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Salt Lake City, Utah", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05861050" }, { "nct_id": "NCT06745076", "title": "Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lugano Classification Stage III Hodgkin Lymphoma AJCC v8", "Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-03-06", "completion_date": "2033-01-03", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 6, "location_summary": "Irvine, California • Palo Alto, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745076" }, { "nct_id": "NCT05636540", "title": "In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "[18F]FluorThanatrace ([18F]FTT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heather Wachtel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-07-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05636540" }, { "nct_id": "NCT03418038", "title": "Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Lymphoma", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Core Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Central Venous Cannula Insertion", "type": "PROCEDURE" }, { "name": "Portacath Placement", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-03-23", "completion_date": "2033-11-02", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 4, "location_summary": "Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more", "locations": [ { "city": "Mankato", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" }, { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03418038" }, { "nct_id": "NCT06032026", "title": "Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Tauopathies" ], "interventions": [ { "name": "11C-HY-2-15 PET", "type": "DRUG" }, { "name": "brain MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Amyloid PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Neurological assessments", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "BEHAVIORAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 70, "start_date": "2023-07-20", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06032026" }, { "nct_id": "NCT05008224", "title": "Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Procarbazine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2021-10-07", "completion_date": "2024-05-26", "has_results": true, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-11-15T14:07:30.067Z", "location_count": 6, "location_summary": "Fullerton, California • Palo Alto, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05008224" } ] }